natgillin/translations-raw huggingface dataset:
Plasma protein binding is on average 85-90%. 
Njegova vezava na plazemske beljakovine je v povprečju od 85 do 90 %.
The effects of these illnesses can be much more severe during treatment with this medicine. 
Učinki teh bolezni so lahko med zdravljenjem s tem zdravilom veliko resnejši.
Press it gently against the roof of your mouth with your tongue until it has dissolved completely (this usually takes about two minutes). 
Z jezikom jo nežno pritisnite ob ustno nebo, dokler se popolnoma ne raztopi (to običajno traja približno dve minuti).
Please also report your vaccination status to your doctor. 
Zdravnika obvestite tudi o svojem statusu cepljenja.
The use of this medicine in children younger than 18 years of age has not yet been studied. 
Uporaba tega zdravila pri otrocih, mlajših od 18 let, še ni raziskana.
In case of short-term overdose no emergency medical treatment is required. 
V primeru kratkotrajnega prevelikega odmerka ni potrebno nujno zdravljenje.
However, no systematic data are available. 
Vendar pa sistematični podatki niso na voljo.
In patients who have not had these diseases, the vaccination status should be checked, and particular care should be taken to avoid exposure. 
Pri bolnikih, ki teh bolezni še niso imeli, je treba preveriti stanje cepljenosti in posvetiti posebno pozornost, da ne pride do izpostavljenosti.
Your doctor will decide on the appropriate measures and if it is still all right for you to take this medicine. 
Zdravnik se bo odločil o primernih ukrepih in ali je še vedno prav, da jemljete to zdravilo.
If you have any of the conditions mentioned above you may be at increased risk of side effects. 
Če imate katero od zgoraj navedenih bolezni, je morda pri vas povečano tveganje za neželene učinke.
The symptoms of some infections can be unusual or less noticeable. 
Simptomi določenih okužb so lahko neobičajni ali manj opazni.
In case your symptoms do not get better in the first 6 weeks of treatment, you may need to take this medicine for up to 6 more weeks. 
Če se vaši simptomi ne izboljšajo v prvih 6 tednih zdravljenja, boste to zdravilo morda morali jemati še do 6 tednov.
For patients who are not appropriately responding during 6 weeks the treatment can be extended to up to 12 weeks. 
Za bolnike, ki se v teh 6 tednih ne odzivajo ustrezno, se zdravljenje lahko podaljša do največ 12 tednov.
Your treatment should last about 6 to 12 weeks. 
Zdravljenje bo trajalo približno 6 do 12 tednov.
The antibody response to other vaccines may be diminished. 
Odziv protiteles na druga cepiva je morda zmanjšan.
Some of these medicines may increase the effects of Jorveza and your doctor may wish to monitor you carefully if you are taking these medicines. 
Nekatera od teh zdravil lahko povečajo učinek zdravila Jorveza in zdravnik vas bo morda želel skrbno spremljati, če jemljete ta zdravila.
Place the orodispersible tablet on the tip of your tongue and close your mouth. 
Orodisperzibilno tableto položite na konico jezika in zaprite usta.
White, round, biplane orodispersible tablet, with diameter of 7.1 mm and height of 2.2 mm. 
Bela, okrogla, ploščata orodisperzibilna tableta s premerom 7,1 mm in višino 2,2 mm.
Take one orodispersible tablet in the morning and one orodispersible tablet in the evening. 
Eno orodisperzibilno tableto vzemite zjutraj in eno orodisperzibilno tableto zvečer.
The total number of infections (including those diagnosed by endoscopy and histology without symptoms) was 33, occurring in 27 out of 87 patients (31%). 
Skupno število okužb (vključno z diagnosticiranimi z endoskopijo in histologijo brez simptomov) je bilo 33, pojavile pa so se pri 27 od 87 bolnikov (31%).
Your doctor will decide how long you are to continue the treatment, depending on your condition and your response to the treatment. 
Vaš zdravnik bo presodil, kako dolgo morate nadaljevati zdravljenje, kar je odvisno od vaše bolezni in vašega odziva na zdravljenje.
However, no systematic study investigating different levels of hepatic impairment is available. 
Vendar pa sistematične študije za preučitev različnih ravni okvare jeter niso na voljo.
Patients with hepatic impairment should not be treated (see sections 4.4 and 5.2). 
Bolnikov z okvaro jeter se ne sme zdraviti (glejte poglavji 4.4 in 5.2).
− Tell your doctor if you have not yet had measles and/or if and when you have received your last vaccination for this disease. 
- Povejte zdravniku, če še niste preboleli ošpic in/ali kdaj ste prejeli zadnje cepljenje za to bolezen.
The treatment with this medicinal product should be initiated by a physician experienced in the diagnosis and treatment of eosinophilic esophagitis. 
Zdravljenje s tem zdravilom mora začeti zdravnik z izkušnjami v diagnosticiranju in zdravljenju eozinofilnega ezofagitisa.
Take the following precautions during treatment with Jorveza because your immune system may be weakened: 
Med zdravljenjem z zdravilom Jorveza upoštevajte naslednje previdnostne ukrepe, ker je vaš imunski sistem lahko oslabljen:
It is important that you do not stop taking your medicine without talking to your doctor. 
Pomembno je, da zdravila ne prenehate jemati, ne da bi se posvetovali z zdravnikom.
Budesonide passes in small amounts into the breast milk. 
Budezonid v majhnih količinah prehaja v materino mleko.
− Keep away from people who have chickenpox or herpes zoster (shingles) if you have not had these infections. 
- Izogibajte se osebam, ki imajo norice ali herpes zoster (pasovec), če sami še niste imeli teh okužb.
This is equivalent to 2.6% of the recommended maximum daily dietary intake of sodium for an adult. 
To je enako 2,6 % največjega priporočenega dnevnega vnosa natrija za odraslo osebo.
− mood changes, such as depression, irritability or euphoria 
- spremembe razpoloženja, kot so depresija, razdražljivost ali evforija;
Budesonide had no effect on fertility in rats. 
Budezonid ni vplival na plodnost pri podganah.
Jorveza with food and drink 
Zdravilo Jorveza skupaj s hrano in pijačo
− Tell your doctor if you get fungal infections in the mouth, throat and gullet or if you think you have any infection during treatment with this medicine. 
- Zdravniku povejte, če se pojavi glivična okužba v ustih, žrelu in požiralniku, ali če menite, da imate med zdravljenjem s tem zdravilom kakšno okužbo.
Use as directed by the physician. 
Uporabljajte v skladu z navodili zdravnika.
Systemic effects of glucocorticosteroids 
Sistemski učinki glukokortikosteroidov
Do not take this medicine during pregnancy without checking with your doctor first. 
Tega zdravila ne uporabljajte med nosečnostjo, ne da bi se najprej posvetovali z zdravnikom.
There should be at least 30 minutes before eating or drinking or performing oral hygiene. 
Vzeti jo je treba najmanj 30 minut pred obrokom ali pijačo oziroma opravljanjem ustne higiene.
Patients showed a 35% increase in peak plasma concentrations and a 60% increase in AUC0-12 compared to healthy subjects. 
Pri bolnikih se je pokazalo 35-% povečanje največje plazemske koncentracije in 60-% povečanje vrednosti AUC0-12 v primerjavi z zdravimi osebami.
The co-administration of live vaccines and glucocorticosteroids should be avoided as this is likely to reduce the immune response to vaccines. 
Izogibati se je treba sočasni uporabi živih cepiv in glukokortikosteroidov, saj je verjetno, da se bo imunski odziv na cepiva zmanjšal.
Jorveza could affect the results of adrenal function tests (ACTH stimulation test) ordered by your doctor or in hospital. 
Zdravilo Jorveza lahko vpliva na rezultate preiskav delovanja nadledvične žleze (stimulacijski test z ACTH), ki jih naroči vaš zdravnik ali jih opravijo v bolnišnici.
If you have taken too many orodispersible tablets on one occasion, take your next dose as prescribed. 
Če ste enkrat vzeli preveč orodisperzibilnih tablet, naslednjič vzemite predpisani odmerek.
Patients with hepatic impairment should therefore not be treated. 
Bolnikov z okvaro jeter se zato ne sme zdraviti.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from the available data). 
Pogostnost je opredeljena kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki
These side effects depend on the duration of treatment, concomitant and previous glucocorticosteroid treatment and the individual sensitivity. 
Ti neželeni učinki so odvisni od trajanja zdravljenja, sočasnega in predhodnega zdravljenja z glukokortikosteroidi in občutljivosti posameznika.
There are currently no data available for patients with renal impairment. 
Trenutno ni na voljo podatkov za bolnike z okvaro ledvic.
Do not take this medicine after the expiry date which is stated on the carton and blister after “EXP”. 
Tega zdravila ne smete jemati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu, poleg oznake »EXP«.
EU/1/17/1254/001 (20 orodispersible tablets) EU/1/17/1254/002 (30 orodispersible tablets) EU/1/17/1254/003 (60 orodispersible tablets) EU/1/17/1254/004 (90 orodispersible tablets) EU/1/17/1254/005 (100 orodispersible tablets) 
EU/1/17/1254/001 (20 orodisperzibilnih tablet) EU/1/17/1254/002 (30 orodisperzibilnih tablet) EU/1/17/1254/003 (60 orodisperzibilnih tablet) EU/1/17/1254/004 (90 orodisperzibilnih tablet) EU/1/17/1254/005 (100 orodisperzibilnih tablet)
The risk of adverse reactions (systemic glucocorticosteroid effects) will be increased. 
Tveganje za neželene učinke (sistemski učinki glukokortikosteroidov) bo večje.
The usual duration of treatment is 6 weeks. 
Zdravljenje običajno traja 6 tednov.
It should be placed on the tip of the tongue and gently pressed against the top of the mouth, where it will dissolve. 
Treba jo je položiti na konico jezika in jo nežno pritisniti ob ustno nebo, kjer se raztopi.
20 orodispersible tablets 30 orodispersible tablets 60 orodispersible tablets 90 orodispersible tablets 100 orodispersible tablets 
20 orodisperzibilnih tablet 30 orodisperzibilnih tablet 60 orodisperzibilnih tablet 90 orodisperzibilnih tablet 100 orodisperzibilnih tablet
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). 
Zdravilo Jorveza je indicirano za zdravljenje eozinofilnega ezofagitisa (EoE) pri odraslih (starejših od 18 let).
Because adrenal function may be suppressed by treatment with budesonide, an ACTH stimulation test for diagnosing pituitary insufficiency might show false results (low values). 
Ker zdravljenje z budezonidom lahko zavira delovanje nadledvične žleze, lahko stimulacijski test z ACTH za diagnostiko insuficience hipofize pokaže napačne rezultate (nizke vrednosti).
CYP3A5 does not contribute significantly to the metabolism of budesonide. 
CYP3A5 ne prispeva bistveno k presnovi budezonida.
Jorveza may cause typical side effects of corticosteroid medicines and may affect all parts of the body, particularly when you take this medicine at high doses and over a long time (see section 4). 
Zdravilo Jorveza lahko povzroči značilne neželene učinke kortikosteroidnih zdravil, ki lahko vplivajo na vse dele telesa, še posebej pri uporabi velikih odmerkov tega zdravila dalj časa (glejte poglavje 4).
Further precautions during treatment with Jorveza − Contact your doctor if you get blurred vision or have other problems with your vision. 
Dodatni previdnostni ukrepi med zdravljenjem z zdravilom Jorveza - Obvestite zdravnika, če se vam pojavi zamegljen vid ali druge težave z vidom.
Concomitant treatment with ketoconazole or other CYP3A4 inhibitors should be avoided (see section 4.5). 
Izogibajte se sočasnemu zdravljenju s ketokonazolom ali drugimi zaviralci CYP3A4 (glejte poglavje 4.5)
When patients are subject to surgery or other stresses, supplementary systemic glucocorticosteroid treatment is therefore recommended. 
Če so bolniki izpostavljeni kirurškemu posegu ali drugim stresnim dejavnikom, je zato priporočljivo dodatno sistemsko glukokortikosteroidno zdravljenje.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from budesonide therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z budenozidom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Pharmacotherapeutic group: Antidiarrheals, intestinal antiinflammatory/antiinfective agents, corticosteroids acting locally, ATC code: A07EA06 
Farmakoterapevtska skupina: antidiaroiki, protivnetna in protimikrobna zdravila, kortikosteroidi z lokalnim delovanjem, oznaka ATC: A07EA06
Other medicines and Jorveza 
Druga zdravila in zdravilo Jorveza
− ketoconazole or itraconazole (to treat fungal infections) 
- ketokonazol ali itrakonazol (za zdravljenje glivičnih okužb),
The glucocorticosteroid activity of the major metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, is less than 1% of that of budesonide. 
Glukokortikosteroidna aktivnost njegovih poglavitnih presnovkov, 6β-hidroksibudezonida in 16α-hidroksiprednizolona, je manjša od 1 % aktivnosti budezonida.
If you have a kidney problem, your doctor will decide if Jorveza is suitable for you. 
Če imate težave z ledvicami, se bo zdravnik odločil, ali je uporaba zdravila Jorveza za vas primerna.
Jorveza has no or negligible influence on the ability to drive and use machines. 
Zdravilo Jorveza nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Chickenpox, herpes zoster and measles can have a more serious course in patients treated with glucocorticosteroids. 
Norice, herpes zoster in ošpice lahko imajo resnejši potek pri bolnikih, zdravljenih z glukokortikosteroidi.
Jorveza should not be used in children and adolescents under 18 years of age. 
Zdravila Jorveza se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Following administration of Jorveza, budesonide is rapidly absorbed. 
Absorpcija Po dajanju zdravila Jorveza se budezonid hitro absorbira.
These measures ensure optimal exposure of the esophageal mucosa to the active substance. 
Ti ukrepi zagotavljajo optimalno izpostavljenost ezofagealne sluznice učinkovini.
This medicine contains 52 mg sodium (main component of cooking/table salt) per daily dose. 
To zdravilo vsebuje 52 mg natrija (glavna sestavina kuhinjske/namizne soli) na dnevni odmerek.
Pack sizes: 20, 30, 60, 90 or 100 orodispersible tablets. 
Velikosti pakiranj 20, 30, 60, 90 ali 100 orodisperzibilnih tablet.
− decreased amount of the hormone cortisol in your blood. 
- utrujenost; - zmanjšana količina hormona kortizola v krvi.
Oestrogens, oral contraceptives 
Estrogeni, peroralni kontraceptivi
Symptoms of fungal infection can be white spots in the mouth and throat and difficulty in swallowing. 
Simptomi glivične okužbe so lahko bele pike v ustih in žrelu ter težave pri požiranju.
The recommended daily dose is 2 mg budesonide as one 1-mg-tablet in the morning and one in the evening. 
Priporočeni dnevni odmerek je 2 mg budezonida v obliki ene 1-mg tablete zjutraj in ene zvečer.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. 
Če se pri bolniku pojavijo simptomi, kot so zamegljen vid ali druge motnje vida, je potrebno razmisliti o napotitvi k oftalmologu zaradi ovrednotenja možnih vzrokov, ki lahko vključujejo katarakto, glavkom ali redke bolezni, kot je centralna serozna horioretinopatija, o katerih so poročali po sistemski in lokalniuporabi kortikosteroidov.
If you take more Jorveza than you should 
Če ste vzeli večji odmerek zdravila Jorveza, kot bi smeli
− If you know that you are due to have an operation please tell your doctor that you are taking Jorveza. 
- Če veste, da boste operirani, povejte zdravniku, da jemljete zdravilo Jorveza.
The recommended dose is two orodispersible tablets (2 mg budesonide) per day. 
Priporočeni odmerek je dve orodisperzibilni tableti (2 mg budezonida) na dan.
Name and address of the manufacturer responsible for batch release 
Ime in naslov izdelovalca , odgovornega za sproščanje serij
Depression, irritability, euphoria, psychomotor hyperactivity, anxiety, aggression 
Psihiatrične motnje depresija, razdražljivost, evforija, psihomotorična hiperaktivnost, anksioznost, agresija
− liver disease. 
- bolezen jeter.
In clinical studies conducted with Jorveza oral, oropharyngeal and esophageal candida infections have been observed with a high frequency (see section 4.8). 
V kliničnih študijah z zdravilom Jorveza so opazili oralne, orofaringealne in ezofagealne okužbe s kandido z veliko pogostnostjo (glejte poglavje 4.8).
It is used in adults (older than 18 years of age) to treat eosinophilic oesophagitis, which is an inflammatory condition of the gullet (food pipe) that causes problems with swallowing food. 
Uporabljamo ga pri odraslih (starejših od 18 let) za zdravljenje eozinofilnega ezofagitisa, ki je vnetna bolezen požiralnika, ki povzroča težave pri požiranju hrane.
Suppression of the inflammatory response and immune function increases the susceptibility to infections and their severity. 
Zaviranje vnetnega odziva in delovanja imunskega sistema poveča tako bolnikovo dovzetnost za okužbe kot resnost okužb.
Although data on the use of inhaled budesonide in a large number of exposed pregnancies indicate no adverse effect, the maximal concentration of budesonide in plasma has to be expected to be higher in the treatment with Jorveza compared to inhaled budesonide. 
Čeprav podatki o uporabi inhalacijskega budezonida pri velikem številu izpostavljenih nosečnosti niso pokazali neželenih učinkov, lahko pri zdravljenju z zdravilom Jorveza pričakujemo višjo najvišjo plazemsko koncentracijo budezonida kot pri inhalacijskem budezonidu.
Alu / Alu-blister. 
Alu/alu pretisni omot.
When ketoconazole was administered approximately 12 hours after budesonide, the plasma concentration of budesonide increased approximately 3-fold. 
Ob dajanju ketokonazola približno 12 ur za budezonidom se je plazemska koncentracija budezonida povečala za približno 3-krat.
Reduced liver function may affect the elimination of budesonide, causing higher systemic exposure. 
Zmanjšano delovanje jeter lahko vpliva na izločanje budezonida, kar povzroča večjo sistemsko izpostavljenost.
The orodispersible tablet should not be taken with liquid or food. 
Orodisperzibilne tablete se ne sme vzeti s tekočino ali hrano.
If you stop taking Jorveza 
Če ste prenehali jemati zdravilo Jorveza
Therefore, concomitant use should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects. 
Zato se je treba sočasni uporabi izogibati, razen kadar koristi odtehtajo povečano tveganje za sistemske neželene učinke kortikosteroidov.
− inflammation of the pancreas, which causes severe pain in the belly and back 
− vnetje trebušne slinavke, ki povzroča hude bolečine v trebuhu in hrbtu;
Pseudotumor cerebri including papilloedema in adolescents 
Bolezni živčevja cerebralni psevdotumor, vključno z edemom papile pri mladostnikih
The safety and efficacy of Jorveza in children and adolescents under the age of 18 years have not been established. 
Pediatrična populacija Varnost in učinkovitost zdravila Jorveza pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
Symptoms of infections can be atypical or masked. 
Simptomi okužb so lahko atipični ali prikriti.
In the treatment of EoE with Jorveza, budesonide inhibits antigen-stimulated secretion of many pro-inflammatory signal molecules such as thymic stromal lymphopoeitin, interleukin-13 and eotaxin-3 in the esophageal epithelium, which results in a significant reduction of the esophageal eosinophilic inflammatory infiltrate. 
Pri zdravljenju EoE z zdravilom Jorveza budezonid zavira antigensko stimulirano izločanje številnih provnetnih signalnih molekul, kot so timusni stromalni limfopoetin, interlevkin 13 in eotaksin 3 v ezofagealnem epiteliju, kar povzroči znatno zmanjšanje ezinofilnih vnetnih infiltratov v požiralniku.
− diabetes, or if somebody in your family has diabetes 
(katarakta) ali če ima kdo v družini glavkom,
- The other ingredients are disodium hydrogen citrate, docusate sodium, macrogol 6000, magnesium stearate, mannitol, anhydrous monosodium citrate, povidone K25, sodium hydrogen carbonate and sucralose (see also section 2, ”Jorveza contains sodium”). 
- Druge sestavine zdravila so dinatrijev hidrogencitrat, natrijev dokusat, makrogol 6000, magnezijev stearat, manitol, brezvodni mononatrijev citrat, povidon K25, natrijev hidrogenkarbonat in sukraloza (glejte tudi konec poglavja 2 »Zdravilo Jorveza vsebuje natrij«).
INFORMATION IN BRAILLE Jorveza 1mg 
PODATKI V BRAILLOVI PISAVI Jorveza 1 mg
During treatment of patients with hepatic impairment with other budesonide containing products, budesonide levels were increased. 
Okvara jeter Med zdravljenjem bolnikov z okvaro jeter z drugimi zdravili, ki vsebujejo budezonid, so bile ravni budezonida povečane.
Because budesonide is not excreted via the kidneys, patients with mild to moderate impairment may be treated with caution with the same doses as patients without renal impairment. 
Ker se budezonid ne izloča skozi ledvice, je pri bolnikih z blago do zmerno okvaro morda potrebna previdnost pri zdravljenju z enakimi odmerki kot pri bolnikih brez okvare ledvic.
Adverse reactions observed in clinical studies with Jorveza are listed in the table below, by MedDRA system organ class and frequency. 
Neželeni učinki, opaženi v kliničnih študijah z zdravilom Jorveza so navedeni v spodnji preglednici, po organskem sistemu MedDRA in pogostnosti.
− general feeling of being ill. 
- splošno slabo počutje.
− if you are allergic to budesonide or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Jorveza: - če ste alergični na budezonid ali katero koli sestavino zdravila (navedeno v poglavju 6).
The orodispersible tablet should be taken after a meal. 
Orodisperzibilno tableto je treba vzeti po obroku.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medicalprescription . 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept s posebnim režimom.
If you have any problem with your kidney or liver, talk to your doctor. 
Če imate težave z ledvicami ali jetri, se posvetujte z zdravnikom.
You should not drink grapefruit juice whilst you are taking this medicine as this can worsen its side effects. 
Med zdravljenjem z zdravilom Jorveza ne smete piti soka grenivke, ker to lahko poslabša neželene učinke zdravila.
Increased risk of thrombosis, vasculitis (withdrawal syndrome after long-term therapy) 
Žilne bolezni povečano tveganje za trombozo, vaskulitis (odtegnitveni sindrom po dolgotrajnem zdravljenju)
Jorveza is not recommended for use in patients with severe renal impairment. 
Uporaba zdravila Jorveza se ne priporoča pri bolnikih s hudo okvaro ledvic.
Do not take this medicine if you are breast-feeding unless you have checked with your doctor. 
Tega zdravila ne uporabljajte, če dojite, razen če ste se posvetovali z zdravnikom.
− weakening of the bones (osteoporosis), bone damage due to poor circulation of blood 
− tanjšanje kosti (osteoporoza), poškodba kostnega tkiva zaradi slabega pretoka krvi (osteonekroza);
If you have any liver disease, you should not take Jorveza. 
Če imate kakršno koli bolezen jeter, ne smete uporabljati zdravila Jorveza.
If indicated, symptomatic candidiasis of the mouth and throat can be treated with topical or systemic anti-fungal therapy whilst still continuing treatment with Jorveza. 
Če je indicirano, se simptomatska kandidiaza ust in žrela lahko zdravi z lokalno ali sistemsko antimikotično terapijo, medtem ko se zdravljenje z zdravilom Jorveza nadaljuje.